

The respiratory test you've been waiting for. CDC encourages laboratories to consider adoption of a multiplexed method during respiratory season, offering diagnosis of overlapping signs and symptoms.¹

- Seasonal respiratory patterns have become unpredictable, necessitating scalable automation.
- COVID-19 and respiratory surges affect testing workflow and staffing.²
- Multiplex respiratory testing can lessen burden on the lab, saving both time and resources.¹
- SARS-CoV-2, influenza A, influenza B and RSV in one test from a single patient sample.

Each year, patients and labs are greatly impacted by these pathogens:



COVID-19 Pandemic: Over 100 million illnesses and over 5.9 million hospitalizations.³



FLU: up to **41 million** illnesses, **710,000** hospitalization⁴



RSV: reported **57,000** children, **177,000** elderly ilnesses⁵



Is It COVID-19, Flu or RSV?

Including COVID-19 with your Flu A, Flu B, and RSV testing provides a crucial testing solution since many of the common symptoms associated with these infections are similar. Testing for these four pathogens concurrently is essential to patient management, as accurate detection leads to effective triaging and treatment, and helps guide infection prevention strategies and provides epidemiologic monitoring.

Get accurate results fast. Prepare for unpredictable respiratory surges with the fully-automated Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay and reduce hands-on time with ready-to-use reagent cartridges.




- Increase throughput with random and continuous access automation, processing up to 335 Panther Fusion® samples in an 8-hour shift and >1000 in 24 hours.6
- Detect additional common respiratory viruses from a single sample with flexible testing algorithms, unique to the Panther Fusion® respiratory portfolio.
- Assay design provides comprehensive strain coverage and the ability to mask any result; positive results include Ct values
- Maximize laboratory and economic efficiencies with full sample-to-result automation, ready-to-use reagents and 60-day onboard stability.

Assay Performance Characteristics⁶

For the qualitative detection and differentiation of SARS-CoV-2, Flu A, Flu B, and RSV in nasopharyngeal samples.

	Prospective		Retrospective	
Analyte	PPA	NPA	PPA	NPA
SARS-CoV-2	96.9%	98.5%	N/A	N/A
Flu A	98.4%	99.7%	93.1%	100%
Flu B	NC	99.8%	95.5%	100%
RSV	84.6%	100%	100%	100%

See PI for complete Clinical Performance.



References: 1. CDC. 07/21/2021: Lab Alert: Changes to CDC RT-PCR for SARS-CoV-2 Testing. https://www.cdc.gov/locs/2021/07-21-2021-lab-alert-Changes_CDC_RT-PCR_SARS-CoV-2_Testing_1.html. Accessed August 11, 2022. 2. CDC. Surge Mitigation in Healthcase. https://www.cdc.gov/coronavirus/2019-ncov/hcp/surge-mitigation.html. Last Reviewed February 8, 2021. Accessed August 11, 2022. 3. CDC. COVID Data Tracker. https://covid.cdc.gov/covid-data-tracker/#clatatracker-home. Accessed February 27, 2023. 4. CDC. Burden of Influenza. https://www.cdc.gov/flu/about/burden/index.html. Accessed August 11, 2022. 5. CDC. Respiratory Syncytial Virus Infection (RSV). Trends and Surveillance. https://www.cdc.gov/rsv/research/us-surveillance.html Last reviewed June 26, 2018. Accessed August 5, 2019. 6. Data on file. 7. Panther Fusion SARS-CoV-2/Flu A/B/RSV [package insert]. AW-27555. San Diego, CA; Hologic, Inc. 2023.

SS-0418-001 Rev. 002 © 2023 Hologic, Inc. All rights reserved. Hologic, Panther Fusion, RespDirect and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or or other countries. This information is intended for medical professionals in the U.S. and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, efforadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to diagnostic.solutions@hologic.com.